Renal Autologous Cell Therapy (REACT) for Chronic Kidney Disease

"For this research to be successful, 15 qualifying individuals must take part. Prokidney will oversee the trial from two sites: Emory University Hospital situated in Atlanta, Georgia and Boise Kidney & Hypertension Institute based in Meridian, Idaho."

"Currently, the trial is operating in 4 parts of the country. These are Atlanta, Meridian and Neptune along with an additional quartet of centres. It's best to opt for a location closest to you if you decide to partake in this medical study so as limit transportation needs."

"Yes, records available on clinicaltrials.gov demonstrate that this medical trial is still recruiting participants. It was first published in August 2019 and updated last October 2022. The trial aims to enrol 15 patients across 4 different sites."

"This trial is enrolling a cohort of 15 individuals with CKD aged 18-65. Crucially, applicants must meet the following conditions: They are male or female and between 18 and 65 years old; they have renal dysfunction resulting from CAKUT; their stage of CKD does not necessitate dialysis; and lastly, at screening, their blood pressure should be below 150/90 before biopsy or injection(s).."

"Our Power team assigned REACT - renal autologous cell therapy a score of 1 for safety, as this Phase 1 trial has yet to yield conclusive evidence on its efficacy and reliability."

"This medical trial stipulates that only those between 18 and 65 years old are eligible for participation. In contrast, 91 clinical studies accept minors while 531 trials accept seniors as their primary demographic."